Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All bromhexine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchBromhexineBromhexine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-Label Randomized Controlled Pilot Study

Li et al., Clinical and Translational Science, doi:10.1111/cts.12881, NCT04273763
Sep 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Discharge 75% Improvement Relative Risk Oxygen therapy 50% Recovery time -3% no CI Bromhexine  Li et al.  LATE TREATMENT  RCT Is late treatment with bromhexine beneficial for COVID-19? RCT 18 patients in China (February - May 2020) Higher discharge (p=0.11) and lower oxygen therapy (p=0.57), not sig. c19early.org Li et al., Clinical and Translational .., Sep 2020 Favorsbromhexine Favorscontrol 0 0.5 1 1.5 2+
Tiny RCT with 12 bromhexine and 6 control patients showing non-statistically significant improvements in chest CT, need for oxygen therapy, and discharge rate within 20 days. Authors recommend a larger scale trial.
Bromhexine efficacy may vary depending on the degree of TMPRSS-dependent fusion for different variants1,2.
risk of no hospital discharge, 75.0% lower, RR 0.25, p = 0.11, treatment 2 of 12 (16.7%), control 4 of 6 (66.7%), NNT 2.0.
risk of oxygen therapy, 50.0% lower, RR 0.50, p = 0.57, treatment 2 of 12 (16.7%), control 2 of 6 (33.3%), NNT 6.0.
recovery time, 3.2% higher, relative time 1.03, treatment 12, control 6.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Li et al., 3 Sep 2020, Randomized Controlled Trial, China, peer-reviewed, 10 authors, study period 16 February, 2020 - 10 May, 2020, trial NCT04273763 (history).
This PaperBromhexineAll
Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‐19: An Open‐Label Randomized Controlled Pilot Study
Ting Li, Laifang Sun, Wenwu Zhang, Chanfan Zheng, Chenchen Jiang, Mingjing Chen, Di Chen, Zhijuan Dai, Shihui Bao, Xian Shen
Clinical and Translational Science, doi:10.1111/cts.12881
This open-label randomized controlled pilot study aimed to test the study feasibility of bromhexine hydrochloride (BRH) tablets for the treatment of mild or moderate coronavirus disease 2019 (COVID-19) and to explore its clinical efficacy and safety. Patients with mild or moderate COVID-19 were randomly divided into the BRH group or the control group at a 2:1 ratio. Routine treatment according to China's Novel Coronavirus Pneumonia Diagnosis and Treatment Plan was performed in both groups, whereas patients in the BRH group were additionally given oral BRH (32 mg t.i.d.) for 14 consecutive days. The efficacy and safety of BRH were evaluated. A total of 18 patients with moderate COVID-19 were randomized into the BRH group (n = 12) or the control group (n = 6). There were suggestions of BRH advantage over placebo in improved chest computed tomography, need for oxygen therapy, and discharge rate within 20 days. However, none of these findings were statistically significant. BRH tablets may potentially have a beneficial effect in patients with COVID-19, especially for those with lung or hepatic injury. A further definitive large-scale clinical trial is feasible and necessary.
References
Chau, SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases, Hepatology
Chen, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet
Depfenhart, Markus, Marina, Dario, De Danielle, A SARS-CoV-2 prophylactic and treatment: a counter argument against the sole use of chloroquine, Am. J. Biomed. Sci. Res
Glowacka, Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response, J. Virol
Guan, Clinical characteristics of coronavirus disease 2019 in China, N. Engl. J. Med
Hatesuer, Tmprss2 is essential for influenza H1N1 virus pathogenesis in mice, PLoS Pathogens
Heurich, Hofmann-Winkler, Gierer, Liepold, Jahn et al., TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein, J. Virol
Hoffmann, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell
Iwata-Yoshikawa, Okamura, Shimizu, Hasegawa, Takeda et al., TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection, J. Virol
Lai, Shih, Ko, Tang, Hsueh, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges, Int. J. Antimicrob. Agents
Lee, The clinical and virological features of the first imported case causing MERS-CoV outbreak in South Korea, BMC Infect. Dis
Limburg, TMPRSS2 is the major activating protease of influenza A virus in primary human airway cells and influenza B virus in human type II pneumocytes, J. Virol
Lucas, The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis, Cancer Discov
Matsuyama, Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells, Proc. Natl. Acad. Sci
Pan, Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia, Radiology
Rodriguez-Morales, Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis, Travel Med. Infect. Dis
Sakai, The host protease TMPRSS2 plays a major role in in vivo replication of emerging H7N9 and seasonal influenza viruses, J. Virol
Tarnow, TMPRSS2 is a host factor that is essential for pneumotropism and pathogenicity of H7N9 influenza A virus in mice, J. Virol
Wang, Wang, Ye, Liu, A review of the 2019 novel coronavirus (COVID-19) based on current evidence, Int. J. Antimicrob. Agents
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and prevention, JAMA
Yang, Yuan, Tu, Determination of bromhexine in plasma by gas chromatography-electron capture detection and pharmacokinetic studies
Yang, Yuan, Tu, Determination of bromhexine in plasma by gas chromatography-electron capture detection and pharmacokinetic studies
Zhang, Shi, Wang, Liver injury in COVID-19: management and challenges, Lancet Gastroenterol. Hepatol
{ 'indexed': {'date-parts': [[2023, 9, 7]], 'date-time': '2023-09-07T20:46:35Z', 'timestamp': 1694119595311}, 'reference-count': 24, 'publisher': 'Wiley', 'issue': '6', 'license': [ { 'start': { 'date-parts': [[2020, 10, 10]], 'date-time': '2020-10-10T00:00:00Z', 'timestamp': 1602288000000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc/4.0/'}], 'content-domain': {'domain': ['ascpt.onlinelibrary.wiley.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2020, 11]]}, 'abstract': '<jats:p>This open‐label randomized controlled pilot study aimed to test the study feasibility ' 'of bromhexine hydrochloride (BRH) tablets for the treatment of mild or moderate coronavirus ' 'disease 2019 (COVID‐19) and to explore its clinical efficacy and safety. Patients with mild ' 'or moderate COVID‐19 were randomly divided into the BRH group or the control group at a 2:1 ' 'ratio. Routine treatment according to China’s Novel Coronavirus Pneumonia Diagnosis and ' 'Treatment Plan was performed in both groups, whereas patients in the BRH group were ' 'additionally given oral BRH (32\xa0mg t.i.d.) for 14 consecutive days. The efficacy and ' 'safety of BRH were evaluated. A total of 18 patients with moderate COVID‐19 were randomized ' 'into the BRH group (<jats:italic>n</jats:italic>\xa0=\xa012) or the control group ' '(<jats:italic>n</jats:italic>\xa0=\xa06). There were suggestions of BRH advantage over ' 'placebo in improved chest computed tomography, need for oxygen therapy, and discharge rate ' 'within 20\xa0days. However, none of these findings were statistically significant. BRH ' 'tablets may potentially have a beneficial effect in patients with COVID‐19, especially for ' 'those with lung or hepatic injury. A further definitive large‐scale clinical trial is ' 'feasible and necessary.</jats:p>', 'DOI': '10.1111/cts.12881', 'type': 'journal-article', 'created': {'date-parts': [[2020, 9, 3]], 'date-time': '2020-09-03T15:07:01Z', 'timestamp': 1599145621000}, 'page': '1096-1102', 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 31, 'title': 'Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‐19: An Open‐Label ' 'Randomized Controlled Pilot Study', 'prefix': '10.1111', 'volume': '13', 'author': [ { 'given': 'Ting', 'family': 'Li', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Anesthesia and Critical Care The Second Affiliated ' 'Hospital and Yuying Children’s Hospital of Wenzhou Medical ' 'University Wenzhou Zhejiang China'}, { 'name': 'Clinical Research Unit The Second Affiliated Hospital and Yuying ' 'Children’s Hospital of Wenzhou Medical University Wenzhou ' 'Zhejiang China'}]}, { 'given': 'Laifang', 'family': 'Sun', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Emergency The Second Affiliated Hospital and ' 'Yuying Children’s Hospital of Wenzhou Medical University Wenzhou ' 'Zhejiang China'}]}, { 'given': 'Wenwu', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Critical Medicine The Second Affiliated Hospital ' 'and Yuying Children’s Hospital of Wenzhou Medical University ' 'Wenzhou Zhejiang China'}]}, { 'given': 'Chanfan', 'family': 'Zheng', 'sequence': 'additional', 'affiliation': [ { 'name': 'Clinical Research Unit The Second Affiliated Hospital and Yuying ' 'Children’s Hospital of Wenzhou Medical University Wenzhou ' 'Zhejiang China'}]}, { 'given': 'Chenchen', 'family': 'Jiang', 'sequence': 'additional', 'affiliation': [ { 'name': 'Clinical Research Unit The Second Affiliated Hospital and Yuying ' 'Children’s Hospital of Wenzhou Medical University Wenzhou ' 'Zhejiang China'}]}, { 'given': 'Mingjing', 'family': 'Chen', 'sequence': 'additional', 'affiliation': [ { 'name': 'Clinical Research Unit The Second Affiliated Hospital and Yuying ' 'Children’s Hospital of Wenzhou Medical University Wenzhou ' 'Zhejiang China'}]}, { 'given': 'Di', 'family': 'Chen', 'sequence': 'additional', 'affiliation': [ { 'name': 'Clinical Research Unit The Second Affiliated Hospital and Yuying ' 'Children’s Hospital of Wenzhou Medical University Wenzhou ' 'Zhejiang China'}]}, { 'given': 'Zhijuan', 'family': 'Dai', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Endocrinology The Second Affiliated Hospital and ' 'Yuying Children’s Hospital of Wenzhou Medical University Wenzhou ' 'Zhejiang China'}]}, { 'given': 'Shihui', 'family': 'Bao', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Pharmacy The Second Affiliated Hospital and Yuying ' 'Children’s Hospital of Wenzhou Medical University Wenzhou ' 'Zhejiang China'}]}, { 'given': 'Xian', 'family': 'Shen', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Gastrointestinal Surgery The Second Affiliated ' 'Hospital and Yuying Children’s Hospital of Wenzhou Medical ' 'University Wenzhou Zhejiang China'}]}], 'member': '311', 'published-online': {'date-parts': [[2020, 10, 10]]}, 'reference': [ { 'key': 'e_1_2_11_1_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijantimicag.2020.105924'}, { 'key': 'e_1_2_11_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijantimicag.2020.105948'}, {'key': 'e_1_2_11_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.2648'}, {'key': 'e_1_2_11_4_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2020.02.052'}, {'key': 'e_1_2_11_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/JVI.02202-13'}, {'key': 'e_1_2_11_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/JVI.02232-10'}, {'key': 'e_1_2_11_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/JVI.00649-19'}, { 'key': 'e_1_2_11_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.34297/AJBSR.2020.08.001283'}, { 'key': 'e_1_2_11_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1158/2159-8290.CD-13-1010'}, { 'key': 'e_1_2_11_10_1', 'unstructured': 'Bisolvon Oral Solution Summary of Product Characteristics Health ' 'Products Regulatory Authority Ireland CRN 2173773 29/04/2016. ' '<https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA0540‐180‐001_19032020145920.pdf>.'}, { 'key': 'e_1_2_11_11_1', 'first-page': '543', 'article-title': 'Determination of bromhexine in plasma by gas chromatography‐electron ' 'capture detection and pharmacokinetic studies [in Chinese]', 'volume': '18', 'author': 'Yang L.L.', 'year': '2000', 'journal-title': 'Se Pu'}, {'key': 'e_1_2_11_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1148/radiol.2020200370'}, { 'key': 'e_1_2_11_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.tmaid.2020.101623'}, {'key': 'e_1_2_11_14_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1073/pnas.2002589117'}, {'key': 'e_1_2_11_15_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/JVI.03799-13'}, {'key': 'e_1_2_11_16_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/JVI.03677-13'}, { 'key': 'e_1_2_11_17_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.ppat.1003774'}, {'key': 'e_1_2_11_18_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/JVI.01815-18'}, { 'key': 'e_1_2_11_19_1', 'first-page': '543', 'article-title': 'Determination of bromhexine in plasma by gas chromatography‐electron ' 'capture detection and pharmacokinetic studies [in Chinese]', 'volume': '18', 'author': 'Yang L.L.', 'year': '2000', 'journal-title': 'Se Pu'}, {'key': 'e_1_2_11_20_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2002032'}, { 'key': 'e_1_2_11_21_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2468-1253(20)30057-1'}, { 'key': 'e_1_2_11_22_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0140-6736(20)30211-7'}, {'key': 'e_1_2_11_23_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/hep.20111'}, { 'key': 'e_1_2_11_24_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s12879-017-2576-5'}], 'container-title': 'Clinical and Translational Science', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12881', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/full-xml/10.1111/cts.12881', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12881', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 9, 4]], 'date-time': '2023-09-04T09:28:34Z', 'timestamp': 1693819714000}, 'score': 1, 'resource': {'primary': {'URL': 'https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.12881'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 10, 10]]}, 'references-count': 24, 'journal-issue': {'issue': '6', 'published-print': {'date-parts': [[2020, 11]]}}, 'alternative-id': ['10.1111/cts.12881'], 'URL': 'http://dx.doi.org/10.1111/cts.12881', 'relation': {}, 'ISSN': ['1752-8054', '1752-8062'], 'subject': [ 'General Pharmacology, Toxicology and Pharmaceutics', 'General Biochemistry, Genetics and Molecular Biology', 'General Medicine', 'General Neuroscience'], 'container-title-short': 'Clinical Translational Sci', 'published': {'date-parts': [[2020, 10, 10]]}, 'assertion': [ { 'value': '2020-05-27', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2020-08-17', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2020-10-10', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit